Dennis J. Carlo, Ph.D. - President, Chief Executive Officer

Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotechnology research and development experience. At Hybritech Inc., the first biotechnology company in San Diego, he served as Vice President of Research and Development and Therapeutic Manufacturing. There, he managed a successful program to carry out research and development in the areas of monoclonal antibody and cancer therapy. After Hybritech was acquired by Eli Lilly & Co in 1985, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberlin, founded The Immune Response Corporation, a public company, where he served in various capacities including Chief Scientific Officer, COO and President and Chief Executive Officer. At The Immune Response Corporation, he established programs in Autoimmunity, Gene Therapy and HIV and led the product development in successful clinical trials. In 1991, while at Immune Response, Dr. Carlo was awarded “Entrepreneur of the Year” by Ernst & Young LLP. From 2003 to 2006, He served as president of Telos Pharmaceuticals, a private biotechnology company. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology.

Robert O. Hopkins - Vice President, Chief Financial Officer

Mr. Hopkins joined Adamis in April 2007 and has been Vice President, Finance and Chief Financial Officer since August 2007. From 2000 to 2004, he was an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. Mr. Hopkins served as Chief Financial Officer of Veritel Corp from 1999 and 2000, a biometric software company. He also served as Chief Operating Officer for Circle Trust Company from 2004 to 2005. From 2005 until Mr. Hopkins joined Adamis in 2007, he consulted for Acumen Enterpises providing analysis and business plans for the various projects. From 1997 to 1999, Mr. Hopkins was Senior Vice President for Finance for the Mariner Post-Acute Network. Among his previous medical-related experience, he has served as Assistant Administrator of Finance for Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America. Mr. Hopkins received a B.S. degree in Finance from Indiana State University and an M.B.A. from Lake Forest Graduate School of Management.

David J. Marguglio - Senior Vice President of Corporate Development

Mr. Marguglio is a co-founder of Adamis and has served as Senior Vice President of Corporate Development and Investor Relations since June 2006. From 1996 to 2006, he held various positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which he successfully sold to a Fortune 100 company. Mr. Marguglio began his career as a financial analyst. He received a degree in finance and management from the Hankamer School of Business at Baylor University.

Ronald B. Moss, M.D. – Chief Medical Officer

Dr. Moss joined Adamis as Chief Medical Officer in February 2017. Prior to joining Adamis, Dr. Moss worked at Ansun Biopharma as CEO and President from October 2012 to February 2017 and as interim CEO from October 2011 to October 2012. Dr. Moss served as Executive Vice President of Clinical Development & Medical Affairs at NexBio from January 2009- October 2011. From June 2006 to January 2009 Dr. Moss served as the Vice President of Clinical Development at Vical Inc. During January 2004- March 2006 he served as the Vice President of Medical Affairs at Telos Pharmaceuticals. Dr. Moss served as the Senior Director of Worldwide Regulatory Affairs for Vaccines/Biologics at Merck and Company from January 2003- January 2004. Dr. Moss joined The Immune Response Corp. in January 1994 as Medical Director and advanced through positions of increasing responsibility and served as the interim President and Chief Executive Officer from August 2002 to January 2003. From July 1993 to January 1994 Dr. Moss served as Assistant Medical Director at Immunization Products Ltd., a joint venture between Rhone-Poulenc Rorer and Immune Response. Dr. Moss trained in Pediatrics at SUNY Stony Brook and completed his Fellowship in Allergy and Clinical Immunology at the National Institutes of Health, and is board certified in allergy & immunology. He is Fellow of the American Academy of Allergy Asthma and Immunology (FAAAI) and a Fellow of the American College of Allergy, Asthma, and Immunology (FCAAI). Dr. Moss is a voluntary faculty member at UCSD School of Medicine Department of Medicine. Dr. Moss earned his M.D. degree at the Chicago Medical School, Rosalind Franklin University of Medicine and Science and his bachelor’s degree from the State University of New York at Stony Brook.

Thomas Moll, Ph.D. - Vice President of Research

Dr. Moll has close to 20 years of experience in both academic and industrial preclinical research and development in the areas of inflammation, immunology and cancer biology. As part of his work, Dr. Moll has gained extensive experience in the generation, production and use of biologics, including protein/Fc chimeras, antibodies and gene therapeutics. After concluding his diploma studies in Biochemistry at the Biocenter, University of Basel, Switzerland, Dr. Moll received his doctorate degree in Genetics and Biochemistry “With Honours” from the University of Vienna, Austria. Subsequent to his work with Boehringer Ingelheim and Sandoz (now Novartis) in Vienna, Austria, Dr. Moll served as Assistant Professor at the University of Muenster, Germany, before joining Cardion AG, a privately held German biotech company. At Cardion, (then Cardiogene) Dr. Moll was initially in charge of the company’s preclinical cardiovascular gene therapy program, before taking over the responsibility for Cardion’s immunology programs as Vice President of Immunology. In this function he supervised the research and preclinical development of several protein/Fc fusion proteins, including CRB-15, an antagonist IL-15/Fc fusion protein. In 2003, Roche Pharmaceuticals licensed this protein for clinical development in various autoimmune disease indications. Before joining the Adamis management team, Dr. Moll was responsible for all research and development activities at Telos Pharmaceuticals. Dr. Moll serves as Editor of the Journal of Immune Based Therapies and has been a member of the European Society of Gene Therapy, the North American Vascular Biology Organization, the American Association of Immunologists, and the American Society of Transplantation.

Karen K. Daniels - Vice President of Operations

Ms. Daniels joined Adamis in July 2009 as Vice President of Operations. She has over 30 years of experience in operational and engineering roles across diverse industries including: electronics, medical devices, contract manufacturing and pharmaceutical manufacturing. Prior to joining Adamis, Ms. Daniels served as President of Althea Technologies from 2007 to 2009. Althea Technologies is a contract manufacturer for the pharmaceutical industry. She also served as Sr. Director of operations and logistics for Vidacare, a medical device manufacturer from 2006 to 2007. Other roles have included President at Lambda Power 2003-2006, General Manager for Plexus Corporation and COO of Qtron which was sold to Plexus (1999-2003). Ms. Daniels has a B.S. degree from the University of Arizona.

Gus Fernandez, Pharm.D., Vice President of Commercial Operations

Dr. Fernandez joined Adamis in March 2015 and serves as Vice President of Operations. He is responsible for the overall planning and execution of Adamis’ commercialization initiatives, as well as new product planning activities for their pipeline compounds. He has over 25 years’ experience in the pharmaceutical industry in a wide variety of functional sectors, which includes sales management, commercial operations, new product planning and business development & licensing. Prior to joining Adamis, Dr. Fernandez served as National Business Director for inVentiv Health from 2011-2015. At inVentiv Health, he was responsible for the development and deployment of a wide variety of sales teams in key therapeutic areas such as oncology, diabetes and influenza. Additionally, Dr. Fernandez has worked in a wide variety of positions of senior level responsibility, which includes Vice President Commercial Development at Avanir Pharmaceuticals, as well as key director level positions at Dura Pharmaceuticals where he served an integral role in the launch and promotion of their products in the asthma, allergy and infectious disease areas. He initiated his career at Eli Lilly and Company with assignments in sales and marketing. Dr. Fernandez received a Doctorate of Pharmacy degree from the University of the Pacific and a Masters of Business Administration from Webster University.